Is AstraZeneca plc Dependent On Debt?

Are debt levels at AstraZeneca plc (LON: AZN) becoming detrimental to its future prospects?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

astrazeneca

Patent problems

As with many major pharmaceutical stocks across the globe, AstraZeneca (LSE: AZN) (NYSE: AZN.US) is struggling to rise to the challenge of generic competition. Indeed, many of its key, blockbuster drugs have seen (or are set to see) their patents expire, with profits from those drugs likely to fall as lower cost copycat drugs hoover up demand.

Acquisition spree

A key part of AstraZeneca’s comeback centres on making acquisitions to fill the void left by drugs such as Crestor, a cholesterol medication, which is due to lose patent protection in 2016. For instance, AstraZeneca recently agreed a $2.7 billion deal with Bristol-Myers Squib to take on its share of the two companies’ diabetes alliance. Several other deals have also been signed in the last year and 2014 looks set to include a number of other acquisitions.

However, is AstraZeneca’s financial firepower sufficient for it embark on further acquisitions? Or is it taking too much risk and becoming dependent on debt?

Debt levels

With a debt-to-equity ratio of 43%, AstraZeneca seems to have plenty of scope to increase debt levels. For instance, sector peer GlaxoSmithKline has a debt-to-equity ratio of 233%. Therefore, on a standalone basis (and on a relative basis), AstraZeneca’s balance sheet does not appear to be at all overly leveraged, with the company having only £0.43 of debt for every £1 of net assets.

Debt coverage

In addition, AstraZeneca has an interest coverage ratio of just under 19. This is extremely comfortable, although it must be pointed out that this is likely to fall somewhat over the next couple of years, as profits decline as a result of the aforementioned patent expiries.

However, the decline should not be a major concern and is likely to leave AstraZeneca with considerable headroom when making the payments on its debt. Furthermore, headroom is sufficient to allow more debt to be taken on (and serviced), which should allow the company to continue with its acquisition spree — even while profits fall over the short to medium term.

Looking ahead

Therefore, AstraZeneca appears to have a relatively high degree of financial firepower with which to counter the ‘patent cliff’ it is currently experiencing. This, allied to an encouraging pipeline, mean that shares could experience a strong 2014 and beyond.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

> Peter owns shares in AstraZeneca. The Motley Fool has recommended shares in GlaxoSmithKline.

More on Investing Articles

Investing Articles

9.4%+ yields! 3 proven FTSE 100 dividend payers I’d buy for my Stocks and Shares ISA

Our writer highlights a trio of FTSE 100 shares with yields close to 10%. He'd happily pop them into his…

Read more »

Mixed-race female couple enjoying themselves on a walk
Investing Articles

Are Raspberry Pi shares a once-in-a-lifetime chance to get rich?

With Raspberry Pi shares surging after a successful IPO, could this UK tech startup offer a long-term wealth creation opportunity…

Read more »

Newspaper and direction sign with investment options
Investing Articles

Huge gains and 9% yields: why now’s an amazing time to be a stock market investor

The stock market’s generating fantastic returns in 2024. Whether you're looking for gains or income, it’s a great time to…

Read more »

Hand of person putting wood cube block with word VALUE on wooden table
Investing Articles

This steady dividend payer looks like one of the best bargain stocks in the FTSE 100

A yield of 4.7% and a consistent dividend record make this FTSE 100 company look like good value in an…

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

£9,000 in savings? That could become passive income of £19,175 a year

It's possible to invest affordable sums of money into building a big passive income stream. Here's how I'd go about…

Read more »

Black father and two young daughters dancing at home
Investing Articles

Legal & General shares: a once-in-a-decade passive income opportunity?

Is a dividend yield at its highest level in a decade, combined with a strong record of increasing payouts, a…

Read more »

Investing Articles

With a 7% yield and 4.1 P/E, is this the best passive income stock on the FTSE 350?

Millions of Britons invest for a passive income. While our writer isn't buying this stock yet, he believes it's worth…

Read more »

Middle-aged Caucasian woman deep in thought while looking out of the window
Investing Articles

This amazing FTSE 250 has a 8.8% dividend yield and trades at just 4x forward earnings!

Our Foolish writer believes this FTSE 250 stock is worth keeping a very close eye on. However, he's not keen…

Read more »